Genstar Capital, a middle-market private equity firm focused on investments in targeted segments of the healthcare, financial services, software and industrial technology industries, has acquired Bracket, a scientifically-driven clinical trial technology and specialty services provider, from Parthenon Capital Partners.

Bracket offers an integrated suite of complementary solutions that help pharmaceutical and biotechnology companies, as well as contract research organizations, maximize clinical data integrity and ultimately improve outcomes with clinical trials. Bracket has over 700 employees and delivers services in more than 90 countries to a diverse base of global customers, including 15 of the top 20 biopharma companies.

Jeff Kinell, chief executive officer of Bracket, commented, "Bracket has built a strong reputation with its customers to help them increase efficiency and outcomes of their clinical trials, with a focus on complex therapeutic areas. Our software and technology-enabled services will become ever more important as our customers increasingly adopt electronic solutions to further improve execution of clinical trials. We were impressed with Genstar's deep understanding of our mission and our value and we are excited to work with Genstar to further execute on growth investments and strategic acquisitions to expand our product capabilities, enter new therapeutic areas, and continue building on our partnerships with our customers."

David Golde, a director at Genstar who leads the firm's pharmaceutical services investing efforts, said, "Bracket is a premier technology solutions provider for pharmaceutical and biotech companies looking to improve the outcomes of their clinical trials. Bracket's comprehensive suite of products and services combined with an unparalleled scientific team have been a driving force behind the company's impressive growth. We are excited to support Jeff Kinell and his team as we share a similar desire to actively pursue growth initiatives and strategic acquisitions to provide increased value to Bracket's customers."

Jean-Pierre Conte, chairman and managing director of Genstar, said, "The addition of Bracket to our portfolio of companies reinforces our commitment to investing in high quality healthcare companies with strong growth drivers that can be further transformed by our active involvement with best in class industry leaders. We are proud and excited to help Bracket navigate its next chapter in its journey of success."

Genstar's current and previous investments in healthcare technology and services companies include ERT, ConnectiveRx, Netsmart, and PRA International.

Bracket was previously a portfolio company of Parthenon Capital Partners, a growth-oriented private equity firm dedicated to building leading companies in healthcare and financial services.